Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Yap TA, et al. Among authors: de bono js. Cancer Discov. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532747 Free PMC article. Clinical Trial.
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: de bono js. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Among authors: de bono js. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Fong PC, et al. Among authors: de bono js. N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24. N Engl J Med. 2009. PMID: 19553641 Free article. Clinical Trial.
Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
Sarker D, Reid AH, Yap TA, de Bono JS. Sarker D, et al. Among authors: de bono js. Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638457 Free article. Review.
514 results